Table 3.
All (n = 94) | Normal RVFWLS (≤−20%) (n = 67) | Abnormal RVFWLS (> −20%) (n = 27) | p value | ||
---|---|---|---|---|---|
SOFA score | n (n missing) |
93 (1) 8 [6, 10] |
67 (0) 7 [6, 10] |
26 (1) 9 [7, 10] |
0.130§ |
Requirement for RRT on day of ECHO | 12 (12.8%) | 6 (9.0%) | 6 (22.2%) | 0.056* | |
Cardiac biomarkers | |||||
hsTn I, ng/L | n (n missing) |
57 (37) 13 [5, 39.5] |
43 (24) 9 [4, 23] |
14 (13) 39.5 [9, 146] |
0.032§ |
hsTn T, ng/L | n (n missing) |
35 (59) 18 [10, 29] |
22 (45) 12.5 [9.3, 19.8] |
13 (14) 27 [21.5, 47] |
< 0.001§ |
Abnormal troponinA | n (n missing) |
92 (2) 41 (44.6%) |
65 (2) 21 (32.3%) |
27 (0) 20 (74.1%) |
< 0.001* |
NT-proBNP, ng/L | n (n missing) |
84 (10) 461 [109, 1798] |
58 (9) 377 [165, 947] |
26 (1) 1697 [302, 23271] |
0.004§ |
Abnormal NT-proBNPB | n (n missing) |
84 (10) 53 (63.1%) |
58 (9) 33 (56.9%) |
26 (1) 20 (76.9%) |
0.079* |
Haemodynamic Parameters | |||||
HR, bpm | n (n missing) |
92 (2) 79 [65, 96] |
67 (0) 77 [63, 95] |
25 (2) 84 [74, 99] |
0.028§ |
Rhythm |
n (n missing) Sinus AF/Flutter |
92 (2) 88 (95.7%) 4 (4.3%) |
67 (0) 64 (95.5%) 3 (4.5%) |
25 (2) 24 (96%) 1 (4%) |
0.703ω |
Mean BP, mmHg | n (n missing) |
89 (5) 77 [71, 87] |
64 (3) 79 [72, 88] |
25 (2) 76 [69, 86] |
0.164§ |
CVP, mmHg | n (n missing) |
59 (35) 7 [3, 12] |
45 (22) 7 [2.5, 12] |
14 (13) 8.5 [4.5, 12.5] |
0.485§ |
Drug Administration | |||||
Vasopressors | 40 (42.6%) | 23 (34.3%) | 17 (63%) | 0.011* | |
Inotropes | 0 (0%) | 0 (0%) | 0 (0%) | NA | |
Anticoagulation | |||||
Prophylactic | 81 (86.2%) | 61 (91%) | 20 (74.1%) | 0.097* | |
Therapeutic | 11 (11.7%) | 5 (7.5%) | 6 (22.2%) | ||
None | 2 (2.1%) | 1 (1.5%) | 1 (3.7%) | ||
Paralysis | 47 (50%) | 34 (50.7%) | 13 (48.1%) | 0.285* | |
Ventilation | |||||
FiO2 | 0.55 [0.45, 0.7] | 0.5 [0.45, 0.65] | 0.55 [0.45, 0.8] | 0.373§ | |
Requirement for prone ventilation in previous 24 h | 35 (37.2%) | 27 (40.3%) | 8 (29.6%) | 0.484* | |
Plateau pressure, cmH2O | n (n missing) |
48 (46) 25 (5.3) |
34 (33) 24.6 (5.6) |
14 (13) 26.1 (4.7) |
0.397η |
PAP, cmH2O | n (n missing) |
91 (3) 26 [19, 30] |
65 (2) 25 [19, 29] |
26 (1) 27 [20, 31] |
0.185§ |
Tidal volume, ml/kg (PBW) | n (n missing) |
89 (5) 6.6 [5.9, 7.3] |
64 (3) 6.5 [5.9, 7.2] |
25 (2) 7.0 [5.9, 7.5] |
0.335§ |
P/F ratio | n (n missing) |
93 (1) 17.5 [12.9, 21.9] |
67 (0) 17.5 [13.3, 21.8] |
26 (1) 17.8 [12.3, 22,5] |
0.918§ |
PEEP, cmH2O | n (n missing) |
93 (1) 10 [8, 12] |
66 (1) 10 [8, 12] |
27 (0) 10 [6, 10] |
0.110§ |
Respiratory rate (/minute) | 25 [21, 28] | 24.6 (5.0) | 24.4 (5.7) | 0.887η | |
Driving pressure, cmH2O | n (n missing) |
48 (46) 13 [11 17.75] |
34 (33) 12 [10, 16.25] |
14 (13) 16.5 [12, 20] |
0.040§ |
Dynamic compliance, ml/cmH2O | n (n missing) |
48 (46) 28.1 [19.1, 39.7] |
34 (33) 31.2 [21.6, 40.1] |
14 (13) 21.2 [16.5, 35.1] |
0.071§ |
Murray lung injury score | n (n missing) |
82 (12) 2.8 [2.3, 3] |
58 (9) 2.8 [2.2, 3] |
24 (3) 2.8 [2.35, 3.2] |
0.479§ |
Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by n (n missing)
A, hsTnT ≥ 15 ng L−1 or hsTnI ≥ 34 ng L−1 for males; ≥ 16 ng L−1 for females. B, NT-proBNP ≥ 300 ng L−1
RVFWLS Right Ventricular Free-wall longitudinal strain, SOFA Sequential organ failure Assessment, RRT Renal Replacement Therapy, hsTn High Sensitivity Troponin, NT-proBNP N-terminal pro B-type Natriuretic Peptide, HR Heart Rate, AF Atrial Fibrillation, BP Blood Pressure; CVP Central Venous Pressure, FiO2 Fraction of Inspired Oxygen, PAP Peak Airway Pressure, PBW Predicted Body Weight, PEEP Positive End Expiratory Pressure
Between-group differences were assessed using Student’s T test (η), Mann–Whitney U test (§), Fisher’s Exact test (ω), and Pearson Chi-Square test (*)